Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 22, 2000

View Archived Issues

Antisoma makes significant progress in product pipeline

Thalidomide improves tolerability of irinotecan in colorectal cancer patients

Genta presents clinical trial update for Genasense

Genzyme General's BLA for Fabry's disease accepted by FDA

Study of pulmonary delivery of patented respiratory drug completed at Sheffield

Antex Pharma licenses new peptides to treat lung diseases

IntraDose receives orphan drug status for melanoma indication

Levaquin tablets/injection approved for new indication in U.S.

Synaptic broadens access to drug design technology

Pierre Fabre and bioMerieux to merge

Roche and BMS form alliance to study Herceptin/Taxol anticancer combination

Italian researchers present newly discovered 5alpha-reductase isoform 1-selective inhibitors

RP-60556A, a new topical antibacterial agent for Gram-positive infections

Baxter and Peptide Therapeutics enter collaboration for vaccine development

Fluticasone more effective than montelukast in asthma control

Korean carbapenem compares favorably to meropenem regarding antibacterial activity, safety

New inhibitors of beta-amyloid fibril formation reported by Novartis

Two recently issued patents cover Pfizer's new PTK inhibitors

Neurotrophic agents with novel profile designed at Schering AG

Shionogi presents new MMP inhibitors with cyclic structure

Factor Xa inhibitors synthesized and tested at AstraZeneca

Preparation and use of new compounds inhibiting fat accumulation described by Sumitomo

Novel calcilytic compounds useful for bone disorders

Spectrum of new ketolide includes susceptible and resistant respiratory tract pathogens

Chiron takes first step towards merger with PathoGenesis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...